Fundz

Immuneering

Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care

Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-d

Key facts

Headquarters
Cambridge, Massachusetts, United States
Employees
Unknown
Industries
Biotechnology, Healthcare, Health Care
Status
Public (IMRX)
Website
immuneering.com
LinkedIn
Company page

Recent activity at Immuneering

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Immuneering funding history

DateRoundAmount
Aug 2025Venture$25.0M
Jan 2021Venture$37.2M
Jan 2020Venture$20.0M
Oct 2019Venture$20.0M

Leadership

  • Joseph Kekst, Director
  • Robert Carpenter, Director
  • Benjamin Zeskind, Executive Officer, Director
  • Grant C. Bogle, MBA, Director
  • Ben Zeskind, Founder
  • Igor Matushansky, Chief Medical Officer

Verified email and direct lines for Immuneering’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Immuneering files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Immuneering in the news

Companies similar to Immuneering

About Immuneering: questions and answers

What does Immuneering do?

Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-d

Where is Immuneering headquartered?

Immuneering is headquartered in Cambridge, Massachusetts, United States.

Has Immuneering raised funding?

Yes. Fundz has recorded 4 funding events for Immuneering. The most recent, $25.0M, was in Aug 2025.

Who leads Immuneering?

Ben Zeskind is a Founder at Immuneering.

What is the latest news on Immuneering?

On Nov 9, 2026, Grant C. Bogle Appointed as Class III Director at Immuneering Corporation

Is Immuneering a public company?

Yes. Immuneering is publicly traded under the ticker IMRX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Immuneering across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.